Authors : Md Afaque Ali; Sani Das; Rajiv Ranjan Kumar; Rabindra Kumar

Volume/Issue : Volume 11 - 2026, Issue 10 - October

---

Google Scholar : https://tinyurl.com/uuezdfwa

DOI : https://doi.org/10.38124/ijisrt/26Oct881

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

---

Abstract : Individuals with Type 2 Diabetes (T2D) who have difficulty regulating their blood glucose levels can use glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are a preferred option for treatment. This review provides a comprehensive overview of the similarities and differences in function between once-weekly GLP-1 RAs, and specifically highlights how pharmacists can provide better medication management, patient education, and overall health outcomes for patients with diabetes.  Methods: This study was a narrative review of the literature regarding the mechanism of action (MoA) of once-weekly GLP-1 RAs that are currently being used to treat T2D.

Keywords : Cardiovascular Diseases, Diabetes Mellitus, Dulaglutide, Exenatide, Glucagon-Like Peptide-1 Receptor Agonist, Glycaemic Control, Mechanism of Action, Semaglutide, Type 2 Diabetes.

References :

1. World Health Organization. Global report on diabetes. World Health Organization; 2016.
2. International Diabetes Federation. IDF Diabetes Atlas, Ninth edi-tion; 2019. https://www.idf.org/e-library/epidemiology-research/ diabetes-atlas/159-idf-diabetes-atlas-ninth-edition-2019.html. Accessed April 21, 2020
3. Mainous AG 3rd, Tanner RJ, Jo A, Anton SD. Prevalence of predia-betes and abdominal obesity among healthy-weight adults: 18-year trend. Ann Fam Med. 2016;14:304-310.
4. American Diabetes Association. Standards of medical care in diabe-tes – 2020. Diabetes Care. 2020;43:S1-S224.
5. Garber AJ, Abrahamson MJ,Barzilay JI, et al. Consensus state-ment by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2019 executive summary. Endocr Pract. 2019;25:69-100.
6. Buse JB, Wexler DJ, Tsapas A, et al. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;2020(43):487-493.
7. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous gluca-gon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741-744.
8. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87:1239-1246.
9. Singh S, Wright EE, Kwan AYM, et al. Glucagon-like peptide-1 re-ceptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2017;19:228-238.
10. Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18:317-332.
11. Doyle ME, Egan JM. Mechanisms of action of GLP-1 in the pan-creas. Pharmacol Ther. 2007;113:546-593.
12. Thrasher J. Pharmacologic management of type 2 diabetes mellitus: available therapies. Am J Cardiol. 2017;120:S4-s16.
13. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728-742.
14. Farr S, Taher J, Adeli K. Glucagon-like peptide-1 as a key regula-tor of lipid and lipoprotein metabolism in fasting and postprandial states. Cardiovasc Hematol Disord Drug Targets. 2014;14:126-136.
15. Goud A, Zhong J, Peters M, Brook RD, Rajagopalan S. GLP-1 ago-nists and blood pressure: a review of the evidence. Curr Hypertens Rep. 2016;18:16.
16. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovas-cular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844.
17. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-322.
18. Amylin Pharmaceuticals. Bydureon® (exenatide extended-release) for injectable suspension, for subcutaneous use prescribing infor-mation; 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022200s026lbl.pdf. Accessed May 17, 2019
19. Novo Nordisk A/S. Ozempic (semaglutide) injection, for subcu-taneous use; prescribing information; 2020. https://www.acces sdata.fda.gov/drugsatfda_docs/label/2020/209637s003lbl.pdf. Accessed January 28, 2020
20. Eli Lilly and Company. Trulicity (dulaglutide) injection for subcuta-neous use; prescribing information; 2020. https://pi.lilly.com/us/ trulicity-uspi.pdf. Accessed April 17, 2020
21. Meece J. The role of the pharmacist in managing type 2 diabetes with glucagon-like peptide-1 receptor agonists as add-on therapy. Adv Ther. 2017;34:638-657.
22. GlaxoSmithKline. Tanzeum (albiglutide) discontinuation; 2017. https://www.tanzeum.com/pdfs/consumer-faq.pdf. Accessed February 28, 2018
23. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987;2:1300-1304.
24. Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155:1280-1290.
25. Wei Y, Mojsov S. Tissue-specific expression of the human re-ceptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett.1995;358:219-224.
26. Novo Nordisk A/S. Victoza® (liraglutide), prescribing information;2019.https://www.novo-pi.com/victoza.pdf. Accessed July 27,2019
27. GlaxoSmithKline LLC. Tanzeum® (albiglutide) for injection, for sub-cutaneous use prescribing information; 2017. https://www.gskso urce.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescrib-ing_Information/Tanzeum/pdf/. Accessed May 17, 2019
28. Amylin Pharmaceuticals. Byetta® (exenatide) injection, prescrib-ing information; 2009. http://www.accessdata.fda.gov/drugs atfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf. Accessed February 28, 2018
29. Sanofi-Aventis US. Adlyxin (lixisenatide), prescribing information; 2016.  http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208471Orig1s000lbl.pdf. Accessed February 28, 2018
30. Fineman MS, Cirincione BB, Maggs D, Diamant M. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab. 2012;14:675-688.
31. Guo XH. The value of short- and long-acting glucagon-like pep-tide-1 agonists in the management of type 2 diabetes mellitus: ex-perience with exenatide. Curr Med Res Opin. 2016;32:61-76.
32. Banting DRA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-795.
33. Kirk RK, Pyke C, von Herrath MG, et al. Immunohistochemical as-sessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes. Diabetes Obes Metab. 2017;19:705-712.
34. Theodorakis MJ, Carlson O, Michopoulos S, et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab. 2006;290:E550-E559.
35. Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev. 2016;32:776-790.
36. Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor ago-nists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19:524-536.
37. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly ver-sus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372:1240-1250.
38. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
39. Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010;33:1255-1261.
40. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control com-pared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:1301-1310.
41. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus lira-glutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381:117-124.
42. Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of du-laglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37:2159-2167.
43. Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014;37:2149-2158.
44. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384:1349-1357.
45. Miyagawa J, Odawara M, Takamura T, Iwamoto N, Takita Y, Imaoka T. Once-weekly glucagon-like peptide-1 receptor agonist dulaglu-tide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. Diabetes Obes Metab. 2015;17:974-983.
46. Nauck MA, Petrie JR, Sesti G, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care. 2016;39:231-241.
47. Kapitza C, Dahl K, Jacobsen JB, Axelsen MB, Flint A. Effects of semaglutide on beta cell function and glycaemic control in par-ticipants with type 2 diabetes: a randomised, double-blind, place-bo-controlled trial. Diabetologia. 2017;60:1390-1399.
48. Korsatko S, Jensen L, Brunner M, et al. Effect of once-weekly semaglutide on the counterregulatory response to hypogly-caemia in people with type 2 diabetes: a randomized, place-bo-controlled, double-blind, crossover trial. Diabetes Obes Metab. 2018;20:2565-2573.
49. Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41:258-266.
50. Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglu-tide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6:275-286.
51. Andreadis P, Karagiannis T, Malandris K, et al. Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2018;20:2255-2263.
52. Odawara M, Miyagawa J, Iwamoto N, Takita Y, Imaoka T, Takamura T. Once-weekly glucagon-like peptide-1 receptor agonist dulaglu-tide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study. Diabetes Obes Metab. 2016;18:249-257.
53. Rosenstock J, Raccah D, Koranyi L, et al. Efficacy and safety of lix-isenatide once daily versus exenatide twice daily in type 2 diabe-tes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care. 2013;36:2945-2951.
54. Rosenstock J, Balas B, Charbonnel B, et al. The fate of taspoglu-tide, a weekly GLP-1 receptor agonist, versus twice-daily exen-atide for type 2 diabetes: the T-emerge 2 trial. Diabetes Care. 2013;36:498-504.
55. Ji L, Onishi Y, Ahn CW, et al. Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabe-tes mellitus. J Diabetes Investig. 2013;4:53-61.
56. Kapitza C, Forst T, Coester HV, Poitiers F, Ruus P, Hincelin-Mery A. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab. 2013;15:642-649.
57. Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inad-equately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2:289-297.
58. Trujillo JM. Safety and tolerability of once-weekly GLP-1 RAs in type 2 diabetes. J Clin Pharm Ther. 2020;45(Suppl. 1):43–60.
59. Sarafidis P, Ferro CJ, Morales E, et al. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A con-sensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant. 2019;34:208-230.
60. Dickson SL, Shirazi RH, Hansson C, Bergquist F, Nissbrandt H, Skibicka KP. The glucagon-like peptide 1 (GLP-1) analogue, exen-din-4, decreases the rewarding value of food: a new role for meso-limbic GLP-1 receptors. J Neurosci. 2012;32:4812-4820.
61. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 pro-motes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101:515-520.
62. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric empty-ing in humans. Diabetes. 2011;60:1561-1565.
63. Gutzwiller J-P, Drewe J, Göke B, et al. Glucagon-like peptide-1 pro-motes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999;276:R1541-R1544.
64. Unni S, Wittbrodt E, Ma J, et al. Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes. Diabetes Obes Metab. 2018;20:468-473.
65. Sun F, Chai S, Li L, et al. Effects of glucagon-like peptide-1 re-ceptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis. J Diabetes Res. 2015;2015:157201.
66. Potts JE, Gray LJ, Brady EM, Khunti K, Davies MJ, Bodicoat DH. The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis. PLoS One. 2015;10:e0126769.
67. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: system-atic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.
68. Ahrén BO, Atkin SL, Charpentier G, et al. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes Obes Metab. 2018;20:2210-2219.
69. Zaccardi F, Htike ZZ, Webb DR, Khunti K, Davies MJ. Benefits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments: a systematic review and network meta-analysis. Ann Intern Med. 2016;164:102-113.
70. Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 di-abetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6:105-113.
71. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228-1239.
72. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and car-diovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121-130.
73. Baggio LL, Yusta B, Mulvihill EE, et al. GLP-1 receptor expression within the human heart. Endocrinology. 2018;159:1570-1584.
74. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like pep-tide 1 receptor are mediated through both glucagon-like peptide1 receptor-dependent and -independent pathways. Circulation. 2008;117:2340-2350.
75. Kim M, Platt MJ, Shibasaki T, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013;19:567-575.
76. Yamamoto H, Kishi T, Lee CE, et al. Glucagon-like peptide-1-re-sponsive catecholamine neurons in the area postrema link periph-eral glucagon-like peptide-1 with central autonomic control sites. J Neurosci. 2003;23:2939-2946.
77. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013;3:e001986.
78. Katout M, Zhu H, Rutsky J, et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens. 2014;27:130-139.
79. Smits MM, Tonneijck L, Muskiet MHA, et al. Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial. Eur J Endocrinol. 2017;176:77-86.
80. Sun F, Wu S, Guo S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110:26-37.
81. Lorenz M, Lawson F, Owens D, et al. Differential effects of glu-cagon-like peptide-1 receptor agonists on heart rate. Cardiovasc Diabetol. 2017;16:6.
82. Sun F, Wu S, Wang J, et al. Effect of glucagon-like peptide-1 recep-tor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. Clin Ther. 2015;37(1):225-241. e8.
83. Hasegawa Y, Hori M, Nakagami T, Harada-Shiba M, Uchigata Y. Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins. J Clin Lipidol. 2018;12(1):62-69.e1.
84. Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20:610-619.
85. Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus in-sulin glargine in patients with type 2 diabetes and moderate-to-se-vere chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6:605-617.
86. Tanaka T, Higashijima Y, Wada T, Nangaku M. The potential for reno-protection with incretin-based drugs. Kidney Int. 2014;86:701-711.
87. Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflamma-tory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia. 2011;54:965-978.
88. Tella SH, Rendell MS. Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. Ther Adv Endocrinol Metab. 2015;6:109-134.
89. Dicembrini I, Nreu B, Scatena A, et al. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes a meta-analysis of randomized controlled trials. Acta Diabetol. 2017;54:933-941.
90. European Medicines Agency. Assessment report for GLP-1 based therapies: Review under Article 5(3) of Regulation (EC) No 726/2004; 2013. https://www.ema.europa.eu/en/documents/ referral/assessment-report-article-53-procedure-glp-1-based-therapies_en.pdf2013. Accessed July 27, 2019
91. Lovshin JA. Glucagon-like peptide-1 receptor agonists: a class up-date for treating type 2 diabetes. Can J Diabetes. 2017;41:524-535.
92. Garcia-Perez LE, Alvarez M, Dilla T, Gil-Guillen V, Orozco-Beltran D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4:175-194.
93. Polonsky WH, Henry RR. Poor medication adherence in type 2 di-abetes: recognizing the scope of the problem and its key contribu-tors. Patient Prefer Adherence. 2016;10:1299-1307.
94. Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008;31:213-224.
95. Lopez JM, Annunziata K, Bailey RA, Rupnow MF, Morisky DE. Impact of hypoglycemia on patients with type 2 diabetes mellitus and their quality of life, work productivity, and medication adher-ence. Patient Prefer Adherence. 2014;8:683-692.
96. Walz L, Pettersson B, Rosenqvist U, Deleskog A, Journath G, Wandell P. Impact of symptomatic hypoglycemia on medication adherence, patient satisfaction with treatment, and glycemic control in patients with type 2 diabetes. Patient Prefer Adherence. 2014;8:593-601.
97. DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly-(D, L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011;13:1145-1154.
98. Goke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9–39)-amide an antagonist at the glucagon-like peptide 1-(7–36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 1993;268:19650-19655.